BeiGene, Ltd. (BEIGF)

Market Cap	24.88B
Revenue (ttm)	3.81B
Net Income (ttm)	-644.79M
Shares Out	n/a
EPS (ttm)	-6.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	499
Open	15.95
Previous Close	19.01
Day's Range	15.95 - 15.95
52-Week Range	11.00 - 16.58
Beta	0.49
RSI	46.61
Earnings Date	May 14, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: BEIGF

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.